MedTrace Logo

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

NCT03435094 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-12-03

No results posted yet for this study

Summary

Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance and on treatment adherence (including compliance and persistence).

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

Binosto 70Mg Effervescent Tablet

Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.

DRUG

Fosamax 70Mg Tablet

Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.

Sponsors & Collaborators

  • Labatec Pharma SA

    lead INDUSTRY

Principal Investigators

  • Aurélie TIREFORD, PharmD · Labatec Pharma SA

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-25
Primary Completion
2022-03-31
Completion
2022-12-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03435094 on ClinicalTrials.gov